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Abstract
Background: The metastasis-promoting protein S100A4 activates the transcription factor NF-κB through the classical 
NF-κB activation pathway. The upstream signal transduction mechanisms leading to increased NF-κB activity are, 
however, incompletely characterized.
Methods: The human osteosarcoma cell line II-11b was stimulated with recombinant S100A4 in the presence or 
absence of inhibitors of common signal transduction pathways, and NF-κB activity was examined using a luciferase-
based reporter assay and phosphorylation of IκBα. mRNA expression was analyzed by real-time RT-PCR, protein 
expression was examined by Western blotting and IKK activity was measured using an in vitro kinase assay. The role of 
upstream kinases and the cell surface receptor RAGE was investigated by overexpression of dominant negative 
proteins and by siRNA transfection.
Results: The Ser/Thr kinase inhibitors H-7 and staurosporine inhibited S100A4-induced IκBα phosphorylation and 
subsequent NF-κB activation. The protein tyrosine kinase inhibitor genistein and the phospholipase C inhibitor 
compound 48/80 had a partial inhibitory effect on IκBα phosphorylation, whereas inhibitors of protein kinase C, G-
protein coupled receptors and PI 3-kinases had no effect on the level of phosphorylation. Interestingly, S100A4 
treatment induced activating phosphorylations of IKKα/β, but neither H-7 nor staurosporine was able to significantly 
inhibit IKK activation. Dominant negative MEKK1 or NIK did not inhibit S100A4-induced NF-κB activity, and S100A4 
stimulation did not influence AKT phosphorylation. Furthermore, diminished expression of the putative S100 protein 
receptor RAGE did not affect the observed phosphorylation of IκBα.
Conclusions: S100A4 activates NF-κB by inducing phosphorylation of IKKα/β, leading to increased IκBα 
phosphorylation. The Ser/Thr kinase inhibitors H-7 and staurosporine attenuated S100A4-induced NF-κB activation 
and inhibited IKK-mediated phosphorylation of IκBα. S100A4-induced NF-κB activation was independent of the 
putative S100 protein receptor RAGE and the Ser/Thr kinases MEKK1, NIK and AKT. These findings lead to increased 
understanding of S100A4 signaling, which may contribute to the identification of novel targets for anti-metastatic 
therapy.
Background
The metastasis-promoting protein S100A4 belongs to the
S100 family of structurally related calcium binding pro-
teins [1,2]. The S100 proteins are expressed in a cell and
tissue specific manner and are involved in a variety of cel-
lular processes, such as cell cycle regulation, cell growth,
differentiation and motility [3]. The protein level of
S100A4 is elevated in several human cancers [1,2], and
expression of the protein is correlated with poor progno-
sis in several malignancies, including breast and colorec-
tal cancer [4,5]. Similar to other S100 proteins, S100A4
possesses both intracellular and extracellular functions.
When applied extracellularly, S100A4 is able to promote
metastasis, stimulate angiogenesis, induce cell motility
and increase expression of matrix metalloproteinases [6-
10]. Even though many of the biological effects are
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described, the mechanisms by which S100A4 exerts these
effects are incompletely understood.
In a previous study we demonstrated increased NF-κB
activity and phosphorylation of JNK (c-Jun N-terminal
kinase) upon stimulation of II-11b cells with extracellular
S100A4 [11]. S100A4-induced activation of NF-κB,
ERK1/2 (extracellular signal-regulated kinase 1/2), p38
MAP kinase and JNK have also been demonstrated in
other cell systems [6,10-13]. However, the connection
between these kinases and NF-κB is not known, and the
upstream mechanisms leading to S100A4-induced NF-κB
activation have not been established. Receptor for
Advanced Glycation End products (RAGE) has been sug-
gested as a putative receptor for several S100 proteins
[14]. RAGE-dependent activation of NF-κB and subse-
quent enhanced MMP-13 expression was observed in
chondrocytes upon stimulation with S100A4 [10], but
RAGE-independent effects have also been described [15].
Through interaction with annexin II S100A4 was able to
induce angiogenesis [8], and in neurons heparan sulfate
proteoglycans were necessary for S100A4-induced neu-
rite extension [15]. Most likely, the protein also acts
through so far unidentified mechanisms, and interaction
with different receptors may explain the various biologi-
cal effects of extracellular S100A4.
The heterodimeric transcription factor NF-κB is a cen-
tral player in cancer development and progression. Sche-
matically, NF-κB can be activated through either the
classical or the alternative pathway. In the classical activa-
tion pathway NF-κB dimers are retained in the cytoplasm
by binding a class of inhibitor proteins, called IκBs. Upon
activation, the IKK (IκB kinase) complex phosphorylates
IκBs and thereby targets the latter for proteasome-medi-
ated degradation. NF-κB dimers can then translocate to
the nucleus where they bind DNA and regulate transcrip-
tion [16].
Here, we demonstrate that extracellular S100A4 stimu-
lates NF-κB activity by inducing phosphorylation of the
IKK complex and subsequent IKK-mediated phosphory-
lation of IκBα. The Ser/Thr kinase inhibitors H-7 and
staurosporine reduced S100A4-induced IκBα phosphory-
lation and NF-κB activation, whereas inhibitors of other
common signaling pathways had a minor or no effect.
The Ser/Thr kinases MEKK1 (MEK Kinase 1), NIK (NF-
κB Inducing Kinase) and AKT (protein kinase B), and the
putative S100A4 receptor RAGE, were not involved in
S100A4-induced NF-κB activation in the cell system
investigated.
Methods
Materials
Mouse recombinant His-S100A4 was produced as previ-
ously described by Haugen et al [17]. Suramin, U-73122,
genistein, AG 18, H-7 and staurosporine were purchased
from Calbiochem (Darmstadt, Germany), GDPβ
(guanosine 5'-[β-thio]diphosphate trilithium salt), com-
pound 48/80 and GF 109203X were obtained from
Sigma-Aldrich (St. Louis, MO), and LY294002 was pur-
chased from Cell Signaling Technology (Beverly, MA).
Cell culture and treatment
The human osteosarcoma cell lines KPDX, the in-house
anti-S100A4 ribozyme transfected osteosarcoma cell line
II-11b and its parent cell line OHS have been described
previously [18-20]. The osteosarcoma cell line U2OS and
the colorectal cancer cell lines HCT 116 and SW620 were
obtained from ATCC (Rockville, MD). Cells were culti-
vated in RPMI-1640 (BioWhittaker, Verviers, Belgium)
containing 8.5% fetal bovine serum (FBS; Biochrome KG,
Berlin, Germany), 20 mM Hepes buffer (Lonza, Verviers,
Belgium), and 2 mM Glutamax (GIBCO BRL, Life Tech-
nologies, Paisley, UK). Human calvarial osteoblasts (lot
number 3417) were obtained from ScienCell Research
Laboratories (Carlsbad, CA) and cultivated in poly-L-
lysine coated flasks in Osteoblast Medium with Osteo-
blast Growth Supplement (ScienCell Research Laborato-
ries, Carlsbad, CA). Subconfluent cultures were
trypsinized and seeded at 6 × 104 cells/cm2 unless other-
wise stated. After overnight incubation, cell culture
medium was replaced with fresh medium in the presence
or absence of signal transduction inhibitors as indicated.
The cells were further incubated for 30 minutes or one
hour prior to addition of 2 μM S100A4, and harvested at
the indicated time points. Relevant solute controls were
included in all experiments
Western blot analysis
Protein lysates were prepared as previously described
[17]. Protease and phosphatase inhibitors were added to
the lysis buffer just before use (10 μg/ml each of leupep-
tin, pepstatin and aprotinin, 1 mM PMSF, 5 mM NaF, 20
mM β-glycerophosphate and 0.5 mM sodium orthovana-
date). Western blotting was performed as described pre-
viously [21], with the exception that protein lysates were
separated on 4-12% NuPAGE® Novex Bis-Tris Gels (Invit-
rogen, Carlsbad, CA) and that 5% non-fat dry milk was
used in the blocking solution (10% for α-tubulin). Pri-
mary antibodies were diluted in 5% non-fat dry milk or
BSA in Tris-buffered saline (TBS) containing the below
noted percentages of Tween 20. Anti-phospho-IκBα
(Ser32/36; 1:2000; 0.05% Tween 20; #9246), anti IκBα
(1:1000; 0.1% Tween 20; #9242), anti-phospho-IKKα/β
(Ser176/180 for IKKα and Ser177/181 for IKKβ; 1:1000;
0.1% Tween 20; #2687) and anti-phospho-AKT (Ser473;
1:500; 0.1% Tween 20; #9271) were obtained from Cell
Signaling Technology (Beverly, MA). Anti-RAGE (1:500;
0.05% Tween 20; sc-80652) was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA), anti-IKKα (1:1000; 0.1%Grotterød et al. BMC Cancer 2010, 10:241
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Tween 20; AF3768) from R&D systems (Minneapolis,
MN), and anti-α-tubulin (1:1000; 0.25% Tween 20; CP06)
from Calbiochem (Darmstadt, Germany). Signals were
visualized using Super Signal West Dura Extended Dura-
tion Substrate (Thermo Scientific, Waltham, MA). Scan-
ning of exposed films were done by CanoScan 9900F
(Canon, Oslo, Norway) and signals quantified by the
KODAK MI v.4.0.1 software (Kodak, New Haven, CT).
Transient transfection and plasmid constructs
The NF-κB activity assay was performed as previously
described [11]. Briefly, cells were transfected with NF-κB
reporter plasmid using electroporation. After overnight
incubation, cells were pretreated with inhibitors followed
by incubation with 2 μM S100A4 for one hour, harvested
and the lysate assayed for luciferase activity using the
Luciferase Assay System (Promega, Madison, WI). Kinase
dead and wild type constructs of MEKK1 (MEKK1 KD
and MEKK1 WT) [22] were purchased from Addgene
(Addgene plasmid 12180 and 12181; Cambridge, MA),
while NIK KD and WT were kind gifts from Dr. Jacques
Piette (Laboratory of Virology and Immunology, Univer-
sity of Liege, Liege, Belgium). MEKK1 and NIK con-
structs were cotransfected with the NF-κB reporter using
the same conditions as described previously [11].
Real-time RT-PCR
RNA isolation was performed using TRI Reagent®
(Ambion/Applied Biosystems, Foster City, CA). Reverse
transcription and real-time PCR was performed as previ-
ously described [23]. 1 μg total RNA was used for cDNA
synthesis, and 1/20 of the reaction mixture employed for
each real-time RT-PCR reaction. YARS (tyrosyl-tRNA
synthetase) was used as housekeeping gene. Primers used
were as previously described [11,24].
Immunoprecipitation
The IKK complex was immunoprecipitated from unstim-
ulated cells and cells treated with 2 μM S100A4 for the
indicated time periods with or without H-7 (30 μM) or
staurosporine (0.4 μM). Cells were harvested and cyto-
p l as m i c  e x t r a cts  i so la t ed  as  d es cri bed  b y  W e r n e r  e t  a l
[25]. 200 μl cytoplasmic extract was incubated with 1 μg
anti-IKKγ (#559675; BD Biosciences, Franklin Lakes, NJ)
for 2 hours at 4°C and subsequently with Protein A aga-
rose-conjugated beads (Amersham Biosciences, Uppsala,
Sweden) for one hour at 4°C. Beads were washed and col-
lected on Costar Spin-X® centrifuge tube filters (Corning
Incorporated, Corning, NY). Proteins were eluted from
the beads by adding warm sample buffer (100 mM Tris-
HCl pH 6.8, 15% glycerol, 3% SDS, 5% β-mercaptoetha-
nol, 0.1% bromophenol blue and 10 mg/ml DTT), fol-
lowed by incubation at 95°C for 1 minute and
centrifugation at 13 000 rpm for 5 minutes. The immuno-
precipitate was separated on 10% NuPAGE® Novex Bis-
Tris Gel (Invitrogen, Carlsbad, CA). After blotting the
membranes were incubated with anti-phospho-IKKα/β
and anti-IKKα.
IKK activity assay
For IKK activity analyses, the IKK complex from unstim-
ulated and S100A4-treated cells was immunoprecipitated
as described above and the kinase reaction performed
according to [25]. Briefly, beads containing precipitated
IKK complex were incubated in 20 μl kinase buffer con-
taining 20 μM ATP (Fermentas, Vilnius, Lithuania), 10
μCi [32P] ATP (Montebello Diagnostics, Oslo, Norway)
and 0.5 μg recombinant human IκBα (Cell Sciences, Can-
ton, MA) for 30 minutes at 30°C with or without H-7 (30
μM) or staurosporine (0.4 μM). The beads were pelleted
by centrifugation, the reaction mixture was resolved on
10% NuPAGE® Novex Bis-Tris Gels (Invitrogen, Carlsbad,
CA) and [32P] IκBα was detected by autoradiography.
Proteins were eluted from the beads as described above,
and the eluate loaded on 10% NuPAGE® Novex Bis-Tris
Gels (Invitrogen, Carlsbad, CA), transferred to Immobi-
lon-P membranes (Millipore, Bedford, MA) and immu-
noblotted using anti-IKKα.
siRNA transfection
siRNA targeting RAGE was designed by use of the Ratio-
nal siRNA Design software [26], with minor modifica-
tions: antisense: 5'-AACCAACUCUCUCCUGUAU-3',
sense: 5'-AUACAGGAGAGAGUUGGUU-3'. Silencer®
Negative Control #1 siRNA (Ambion/Applied Biosys-
tems, Foster City, CA) was used as negative control. Lipo-
fectamine (Invitrogen, Carlsbad, CA) was used in
concentration of 2 μl/ml and cell transfection performed
in Opti-MEM (Invitrogen, Carlsbad, CA) according to
the manufacturer's procedure. Transfection mixtures
contained 50 nM siRNA and the complex was added to
106 cells seeded in T-25 bottles using reverse transfection.
After 24 hours incubation, fresh cell culture medium was
added and the cells incubated further for 24 hours. Cells
were then stimulated with 2 μM S100A4 for one hour and
harvested for protein isolation as described above.
Statistical analysis
All statistical analyses were performed using two-tailed
Student's t-test. Cells treated with S100A4 and H-7/stau-
rosporine were compared to S100A4-stimulated cells
without inhibitor. P-values less than 0.05 were considered
to be statistically significant.
Results
Signal transduction mechanisms involved in S100A4-
induced NF-κB activation and expression of target genes
We have previously reported that S100A4 stimulates NF-
κB activity through the classical activation pathway in the
II-11b cell line, by demonstrating increased phosphoryla-Grotterød et al. BMC Cancer 2010, 10:241
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tion of IκBα [11]. To investigate the upstream signal
transduction mechanisms involved in S100A4-induced
NF-κB activation, II-11b cells were treated with inhibitors
of various signal transduction pathways: Ser/Thr kinases
(H-7 and staurosporine), phospholipase C (U-73122 and
compound 48/80), protein tyrosine kinases (AG 18 and
genistein), protein kinase C (GF 109203X), G-protein
coupled receptors (GDPβ and suramin) and phosphati-
dylinositol 3-kinases (PI 3-kinases; LY294002). The levels
of phosphorylated IκBα were used to measure activity in
the NF-κB pathway. The Ser/Thr kinase inhibitors H-7
and staurosporine reduced IκBα phosphorylation levels
in a dose dependent manner (Fig. 1A and 1B). A partial
inhibitory effect was observed with genistein and com-
pound 48/80 at the highest concentrations, whereas no
inhibition was observed with the other signal transduc-
tion inhibitors (Fig. 1C-J). Based on these initial experi-
ments, H-7 and staurosporine were chosen for further
studies. As previously shown [11], total IκBα expression
levels were reduced upon treatment with S100A4 (Fig. 2A
and 2B; compare lanes 1 and 2). In S100A4-stimulated
cells, increasing concentrations of H-7 or staurosporine
resulted in decreased levels of IκBα (Fig. 2A and 2B; com-
pare lanes 4, 6, 8 and 10 with lane 2). IκBα expression was
also reduced in cells treated with staurosporine alone.
Importantly, H-7 and staurosporine displayed a potent
and dose dependent inhibition of S100A4-induced NF-κB
activation in a luciferase based activity assay, both using
II-11b cells (Fig. 3A and 3B) and the human osteosarcoma
cell line KPDX (Fig. 3C). Recently, we demonstrated that
S100A4 augmented expression of ephrin-A1 and
optineurin in II-11b cells, and that the induction was
dependent on NF-κB activity [11]. Addition of H-7 or
staurosporine suppressed S100A4-induced expression of
these target genes in a dose dependent manner (Fig. 4).
Taken together, these findings indicate that Ser/Thr
kinases are central players in S100A4-induced NF-κB
activation.
S100A4 induces phosphorylation of IKKα/β
The IKK complex consists of the two catalytic subunits
IKKα and IKKβ and the regulatory subunit IKKγ/NEMO.
In the classical NF-κB activation pathway IKKα and IKKβ
are activated by phosphorylation of specific serine resi-
dues in the activation loop, and is thereby able to induce
serine phosphorylation of IκBα [27]. By immunoprecipi-
tating the IKK complex from S100A4-stimulated II-11b
cells, and subsequently subject the precipitate to immu-
noblotting using a phosphospecific IKKα/β antibody, a
time dependent induction of IKKα/β phosphorylation
was detected (Fig. 5A).
Figure 1 Dose dependent reduction in phosphorylation of IκBα by Ser/Thr kinase inhibitors. II-11b cells were pretreated with the inhibitors H-
7 (A), staurosporine (B), U-73122 (C) compound 48/80 (D), AG 18 (E), genistein (F), GF 109203X (G), GDPβ (H), suramin (I) or LY294002 (J) using the in-
dicated concentrations. Thereafter, cells were stimulated with 2 μM S100A4 for one hour, harvested and analyzed by immunoblotting for expression 
of phosphorylated IκBα and α-tubulin. The figures shown are representative of two or three independent experiments.
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Inhibitors of Ser/Thr kinases suppress IKK-mediated 
phosphorylation of IκBα
The observed suppression of S100A4-induced IκBα phos-
phorylation and NF-κB activation by H-7 and stauro-
sporine could be caused by inhibition of several kinases
in the activation pathway. Searching for involved kinases
upstream of IκBα, it was of interest to investigate whether
H-7 and staurosporine were able to inhibit IKK kinase
activity or kinases upstream of IKK. In order to investi-
gate this, the IKK complex was immunoprecipitated from
untreated and S100A4-stimulated cells and incubated
with recombinant IκBα and radioactive ATP to measure
Figure 2 Dose dependent reduction in phosphorylated IκBα and total IκBα in S100A4-stimulated cells by Ser/Thr kinase inhibitors. II-11b 
cells were treated with 2 μM S100A4 and the inhibitors H-7 (A) and staurosporine (B) using the indicated concentrations. After one hour cells were 
harvested and analyzed by immunoblotting for expression of phosphorylated IκBα, total IκBα and α-tubulin as indicated. For total IκBα both short and 
long exposure times are shown.
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Figure 3 H-7 and staurosporine inhibit S100A4-induced NF-κB activity. II-11b (A and B) and KPDX (C) cells transfected with an NF-κB luciferase 
reporter construct were incubated with H-7 or staurosporine prior to S100A4-stimulation. NF-κB activity is expressed as relative induction upon 
S100A4 treatment compared to relevant control. Bars represent mean values ± S.E of three independent experiments performed in triplicate or du-
plicate. St = staurosporine. *, p < 0.05Grotterød et al. BMC Cancer 2010, 10:241
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in vitro kinase activity. Fig. 5B and 5C show that S100A4
treatment increased the ability of IKK to phosphorylate
IκBα in vitro, while the presence of H-7 or staurosporine
reduced IKK-mediated IκBα phosphorylation. To exam-
ine whether H-7 or staurosporine affected S100A4-
induced activation of the IKK complex, levels of phos-
phorylated IKKα/β were analyzed in untreated and
S100A4-stimulated cells with or without H-7 or stauro-
sporine added to the cell culture medium. A small reduc-
tion in phosphorylated IKKα/β was achieved in one of
three experiments using staurosporine, whereas H-7 did
not suppress the phosphorylation levels (Fig. 5D and 5E).
Taken together these results indicate that neither H-7 nor
staurosporine inhibits S100A4-induced activation of the
IKK complex, while both inhibitors are able to hinder
IKK-mediated phosphorylation of IκBα in vitro.
S100A4-induced NF-κB activation is independent of the 
Ser/Thr kinases MEKK1, NIK and AKT
Previously, we demonstrated JNK phosphorylation after
S100A4 treatment of II-11b cells [11]. MEKK1 is a possi-
ble common upstream kinase responsible for activating
both the IKK complex and JNK [28]. It was therefore of
interest to examine whether this kinase could be involved
Figure 4 S100A4 target gene expression is reduced by H-7 and staurosporine. Real-time RT-PCR demonstrating dose dependent inhibition of 
ephrin-A1 mRNA (A and C) and optineurin mRNA (B and D) expression in II-11b cells stimulated for 2 hours with 2 μM S100A4 in presence of the indi-
cated concentrations of H-7 (A and B) or staurosporine (C and D). Bars represent mean values ± S.E of three independent experiments. St = stauro-
sporine. *, p < 0.05Grotterød et al. BMC Cancer 2010, 10:241
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Figure 5 A. S100A4 induces phosphorylation of IKKα/β. Western blot of immunoprecipitated IKK complex from II-11b cells treated with 2 μM 
S100A4 for the indicated time periods and analyzed for expression of phosphorylated IKKα/β. IKKα was used as loading control. B. H-7 and stauro-
sporine inhibit IKK-mediated IκBα phosphorylation in vitro. Upper panel: Kinase assay showing phosphorylation of recombinant IκBα by immunopre-
cipitated IKK complex from unstimulated II-11b cells or cells stimulated with 2 μM S100A4 for 15 minutes, with or without H-7 (30 μM) or staurosporine 
(0.4 μM) present in the reaction mixture. Lower panel: Western blot showing IKKα as a loading control. C. Densitometric quantification of the signals 
shown in Fig. 5B. The bars show IκBα phosphorylation relative to IKKα expression. One of three independent experiments is quantified due to high 
background in the other experiments. D. Treatment with H-7 or staurosporine did not influence the level of phosphorylated IKKα/β upon S100A4-
stimulation for 15 minutes. Immunoprecipitated IKK complex was analyzed by immunoblotting using anti-phospho IKKα/β antibody. IKKα is used as 
loading control. E. Densitometric quantification of Fig. 5D. Bars show phosphorylated IKKα/β relative to IKKα expression. B and D are representative 
results of three independent experiments. St = staurosporine.Grotterød et al. BMC Cancer 2010, 10:241
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in S100A4-induced activation of NF-κB. However, no sig-
nificant effect was observed on S100A4-induced IκBα
phosphorylation or NF-κB activation when dominant
negative MEKK1 was overexpressed (Fig. 6A and 6B). It
has also been shown that the Ser/Thr kinases NIK and
AKT could be involved in phosphorylation and activation
of the IKK complex [29,30]. As for MEKK1, dominant
negative NIK was not able to inhibit S100A4-mediated
IκBα phosphorylation or NF-κB activation (Fig. 6A and
6B). Wild type MEKK1 and NIK was used in experiments
to verify that the dominant negative constructs were able
to suppress NF-κB activation induced by MEKK1 or NIK
(Fig. 6C). Moreover, AKT phosphorylation at serine resi-
due 473 was unaffected by treatment with S100A4 (Fig.
6D). AKT is normally phosphorylated after PI 3-kinase
activation, and the finding that LY294002 had no effect
on IκBα phosphorylation strengthens the conclusion that
AKT is not involved in S100A4-induced IKK activation.
S100A4-mediated NF-κB activation is RAGE-independent
RAGE has been suggested as receptor for several S100
proteins. In an attempt to investigate the possible role of
RAGE in S100A4-induced NF-κB signaling, siRNA mole-
cules targeting RAGE mRNA were utilized. Fig. 7A shows
that S100A4 induces phosphorylation of IκBα to the same
extent even with RAGE expression levels substantially
reduced by siRNA transfection. Furthermore, RAGE
expression in a panel of cell lines previously analyzed for
NF-κB activation [11] was investigated, and no associa-
tion between RAGE levels and S100A4-induced NF-κB
activation was observed (Fig. 7B). Finally, S100A4-medi-
ated phosphorylation of IκBα was detected in human
osteoblasts expressing low levels of RAGE (Fig. 7C). Alto-
gether, these results indicate that RAGE is not involved in
S100A4-induced NF-κB activation.
Discussion
S100A4-induced activation of the transcription factor
NF-κB has been reported in several cell systems [6,10,13],
but the mechanisms responsible for the enhanced activity
are only partly elucidated. We have previously reported
that S100A4 activates NF-κB through the classical activa-
tion pathway in the II-11b cell line [11], and the present
study was initiated to reveal upstream signal transduction
mechanisms leading to phosphorylation of IκBα. By using
inhibitors of common signal transduction pathways, Ser/
Thr kinases were found to be essential for S100A4-
induced NF-κB activation. Inhibitors of phospholipase C,
protein tyrosine kinases, protein kinase C, G-protein cou-
pled receptors and PI 3-kinases had only a minor or no
effect on IκBα phosphorylation in the examined osteosar-
coma cell system. S100A4 was for the first time demon-
strated to induce IKKα/β phosphorylation. The employed
Ser/Thr kinase inhibitors H-7 and staurosporine were
able to inhibit the subsequent IKK-mediated phosphory-
lation of IκBα, NF-κB activation and expression of target
genes, whereas the same inhibitors did not affect activa-
tion of the IKK complex. RAGE, previously suggested as a
receptor for extracellular S100A4 and a well-known acti-
vator of NF-κB signaling, was not involved in S100A4-
induced NF-κB activation.
Both IκBα and subunits of the IKK complex are phos-
phorylated on serine residues. It was therefore of interest
to examine whether IKK kinase activity or kinases
upstream of IKK were suppressed by the added Ser/Thr
kinase inhibitors. By utilizing immunoprecipitated IKK
complex from S100A4-stimulated cells in an in vitro
k i n a s e  a s s a y ,  b o t h  i n h i b i t o r s  w e r e  d e m o n s t r a t e d  t o
reduce IKK-mediated phosphorylation of IκBα. However,
the phosphorylation status of the catalytic IKK subunits
IKKα and IKKβ were not influenced. The molecular
mechanisms of IKK activation have at present not been
fully elucidated, but activity is known to depend on phos-
phorylation of serine residues in the activation loop of
IKKα and IKKβ (as detected by the antibody utilized; Fig.
5). This may occur through direct phosphorylation by an
upstream kinase, or by trans-autophosphorylation
through induced proximity of IKKα/β as a result of IKK
multimerization [27]. Because H-7 and the broad spec-
trum kinase inhibitor staurosporine are able to inhibit
IKK-mediated IκBα phosphorylation, one might expect
that IKK autophosphorylation also would be suppressed
by these inhibitors. In our experiments, IKK phosphory-
lation was not affected by H-7 and staurosporine, sug-
gesting that an upstream serine kinase could be
responsible for the S100A4-mediated IKKα/β phosphory-
lation. In that event, there are at least three potential
explanations for the lack of inhibition by H-7 and stauro-
sporine: (i) the upstream serine kinase is not inhibited by
the Ser/Thr kinase inhibitors employed; (ii) the inhibitors
were unable to significantly inhibit the upstream kinase at
the concentrations and experimental conditions used in
our experiments; and (iii) given that signaling compo-
nents often are functionally redundant, alternative path-
ways could be activated, masking the inhibitory effect of
the particular inhibitor added. Several kinases have been
shown to participate in activation of the IKK complex,
including the Ser/Thr kinases MEKK1, NIK and AKT
[27-31]. Assuming that an upstream serine kinase is
involved in S100A4-induced IKK activation, these candi-
dates were further investigated. However, in the II-11b
cell line no increase in AKT phosphorylation was
observed upon stimulation with S100A4, and dominant
negative NIK and MEKK1 had no effect on S100A4-
induced NF-κB activation.
The finding that total IκBα levels decreased in S100A4-
stimulated cells with increasing concentrations of H-7
and staurosporine was somewhat surprising, and thisGrotterød et al. BMC Cancer 2010, 10:241
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Figure 6 The Ser/Thr kinases MEKK1, NIK and AKT are not involved in S100A4-mediated activation of the IKK complex. A. Representative 
Western blots of II-11b cells transfected with dominant negative constructs of MEKK1 or NIK (2 μg), stimulated with S100A4 for one hour and analyzed 
for expression of phosphorylated IκBα. B. Cotransfection of II-11b cells with NF-κB luciferase reporter construct and dominant negative MEKK1 or NIK 
(2 μg) as described in "Methods". Bars show relative induction of NF-κB activity upon S100A4 treatment compared to relevant control. KD = kinase 
dead. C. Control experiment to evaluate the ability of the dominant negative MEKK1 and NIK constructs to suppress NF-κB activity. Empty vector was 
used as transfection control and to adjust the amount of plasmid in each transfection. D. Western blot of II-11b cells treated with 2 μM S100A4 for the 
indicated time periods, analyzed for levels of phosphorylated AKT and α-tubulin. A, B and D are representative results of three independent experi-
ments.Grotterød et al. BMC Cancer 2010, 10:241
http://www.biomedcentral.com/1471-2407/10/241
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observation may have at least two explanations. First,
IκBα expression is reduced in cells treated with stauro-
sporine alone, indicating that the mechanism is partly
S100A4-independent. Second, NF-κB stimulates IκBα
transcription as part of a negative feedback mechanism,
and the total level of IκBα thus represent the net result of
protein degradation and resynthesis. In the II-11b cell
line we have previously shown that S100A4-mediated
NF-κB activation stimulates transcription of IκBα [11].
Furthermore, the NF-κB transcription complex consists
of several proteins, and multiple serine phosphorylations
are required for optimal activation [32]. By affecting any
of these phosphorylations H-7 and staurosporine may
inhibit NF-κB activation, and total IκBα levels may as a
consequence decrease upon treatment with S100A4 and
the inhibitors compared to S100A4 alone. Nevertheless,
the importance and biological relevance of S100A4-
induced IκBα phosphorylation is confirmed by previous
data showing that S100A4-mediated NF-κB activation is
dependent on IκBα phosphorylation at Ser32/36 [11].
The protein tyrosine kinase inhibitor genistein and the
phospholipase C inhibitor compound 48/80 displayed a
partial inhibition of S100A4-induced IκBα phosphoryla-
tion, but we were not able to confirm these results using
other inhibitors of the same signaling pathways (AG 18
and U-73122, respectively). Furthermore, inhibitors of
protein kinase C, G-protein coupled receptors and PI 3-
kinases were unable to affect S100A4-mediated IκBα
phosphorylation. Except for PI 3-kinases, the above men-
tioned mediators have previously been reported involved
in S100A4-induced signaling [10,12,15], and the seem-
ingly conflicting results may be explained by cell line spe-
cific differences, for instance in expression of cell surface
receptors or intracellular signal transduction molecules.
As discussed above, functional redundancy may also
explain the divergent results.
The effect of S100A4 on IKK phosphorylation was
detected as early as after 10 minutes, indicating receptor-
mediated transduction of the signal from the extracellular
environment to intracellular effector molecules. Many
S100 proteins have been found to transduce their effects
through RAGE, but RAGE-independent effects have
been observed both for S100A4 and other S100 proteins
[14]. NF-κB activation is a well-known downstream event
of RAGE signaling, and NF-κB activation by S100A4 [10],
S100A1 [33], S100A8/A9 [34], S100A12 [35], S100B [33]
and S100P [36] has been shown to be RAGE-dependent
in certain cell systems. Therefore, we examined the
involvement of RAGE in S100A4-induced NF-κB activa-
tion in II-11b cells. Using siRNA molecules targeting
RAGE mRNA, expression was substantially reduced
without observing any effect on S100A4-stimulated IκBα
phosphorylation. The exact protein expression levels of
RAGE necessary to maintain downstream signal trans-
duction is not known, but the observed reduction in
RAGE expression was more pronounced than in other
studies demonstrating RAGE-dependent effects [34],
suggesting that the observed S100A4-mediated activation
of NF-κB is RAGE-independent. Accordingly, S100A4-
induced neurite outgrowth occurs through RAGE-inde-
pendent mechanisms [15], and extracellular S100A4
stimulates motility and activates NF-κB in cells that do
not express RAGE mRNA [6,7].
Figure 7 RAGE-independent NF-κB activation upon S100A4-
stimulation of II-11b cells. A. Western blot showing reduced RAGE 
protein expression by siRNA transfection. 48 hours after transfection 
the cells were stimulated with S100A4 for one hour and cell lysates 
subjected to immunoblotting using anti-phospho-IκBα. The results 
shown are representative of three independent experiments. siNC = 
siRNA negative control. B. Western blot showing RAGE expression in a 
panel of cell lines. NF-κB activation refers to the levels of S100A4-in-
duced NF-κB activation demonstrated in a previous study [11], except 
for osteoblasts, where it refers to IκBα phosphorylation levels shown in 
Fig. 7C. C. Western blot showing IκBα phosphorylation in human os-
teoblasts after S100A4 stimulation for the indicated time periods. α-tu-
bulin was used as loading control.
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Signaling through RAGE is clearly responsible for bio-
logical effects induced by extracellular S100A4 in certain
cell systems, but other cell surface molecules have also
been suggested to be involved in S100A4 signaling. Neu-
rite outgrowth mediated by S100A4 was partly dependent
on interaction with heparan sulfate proteoglycans at the
cell surface [15], and other S100 proteins also bind hepa-
ran sulfate moieties [37]. In the II-11b cell line treatment
with heparin had no effect on S100A4-induced NF-κB
activation (results not shown), indicating that S100A4-
induced NF-κB signaling is not dependent on interaction
with glycosaminoglycans at the cell surface. On endothe-
lial cells, S100A4 interacts with annexin II, which acts as a
coreceptor governing the assembly of S100A4, plasmino-
gen and its activators [8]. However, annexin II is not
known to propagate intracellular signals upon binding to
S100A4. Altogether, our findings suggest that a so far
unidentified cell surface receptor mediates S100A4-
induced NF-κB activation.
Conclusions
Extracellular signals enhancing tumor cells metastatic
capacity might be attractive candidates for therapeutic
intervention. One such candidate is the metastasis-pro-
moting protein S100A4. In the present study we used a
human osteosarcoma cell line to demonstrate that extra-
cellular S100A4 activates the IKK complex and induces
NF-κB activity independent of the postulated S100 recep-
tor RAGE. Further studies to identify possible S100A4
specific receptor molecule(s) and induced downstream
signaling pathway(s) may identify targets that can be uti-
lized in anti-metastatic therapy.
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